Recent Updates
Recently added Catalysts
BRKR Positive Sentiment

Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development

Key Takeaway: Bruker Corporation has announced a majority investment in MIMETAS B.V., a company specializing in organ-on-a-chip platforms and advanced human tissue models. This investment aims to enhance Bruker's post-genomic solutions for disease biology and drug development. The collaboration will focus on Microphysiological Systems, which are crucial for advancing drug discovery methodologies.

Market Sentiment Analysis

POSITIVE FACTORS

  • Bruker expands its capabilities in drug discovery.
  • Investment in MIMETAS enhances human physiology-relevant research.
  • Focus on innovative organ-on-a-chip technology.

Full Press Release Details

LEIDEN, The Netherlands--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced a majority investment in MIMETAS B.V., a developer of organ-on-a-chip platforms and advanced human tissue and disease models for drug discovery and development. The investment expands Bruker’s post-genomic solutions for disease biology research, as well as for drug discovery and development into Microphysiological Systems (MPS), also referred to as New Approach Methodologies (NAMs), and based on human ph

Frequently Asked Questions

What is the purpose of Bruker's investment in MIMETAS?

The investment aims to enhance drug discovery and development using advanced human tissue models.

What technology does MIMETAS specialize in?

MIMETAS specializes in organ-on-a-chip platforms for drug discovery.

How will this investment benefit Bruker?

It expands Bruker's post-genomic solutions for disease biology research.

What are Microphysiological Systems?

Microphysiological Systems are innovative methodologies for drug discovery based on human physiology.

Last updated: Aug 10, 2026